Skip to main content

LCD L39400: Magnesium

LCD L39400, Magnesium, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2024-09-12 and first in force 2023-01-22. The policy text runs 441 words, and its billing and coding article A59186 lists 4,360 ICD-10-CM codes that support medical necessity for 1 procedure code. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2024-09-12
Original effective
2023-01-22
Policy text
441 words
Covered ICD-10 codes (articles)
4360

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39400
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A59186: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59186 (Billing and Coding: Magnesium) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

A59186: Billing and Coding: Magnesium (Billing and Coding, effective 2026-10-01)

Covered ICD-10-CM codes
4360
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A59186
ICD-10-CMDescription (FY2027)
C13.0Malignant neoplasm of postcricoid region
C13.1Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect
C13.2Malignant neoplasm of posterior wall of hypopharynx
C13.8Malignant neoplasm of overlapping sites of hypopharynx
C13.9Malignant neoplasm of hypopharynx, unspecified
C15.3Malignant neoplasm of upper third of esophagus
C15.4Malignant neoplasm of middle third of esophagus
C15.5Malignant neoplasm of lower third of esophagus
C15.9Malignant neoplasm of esophagus, unspecified
C76.0Malignant neoplasm of head, face and neck
C76.1Malignant neoplasm of thorax
C76.2Malignant neoplasm of abdomen
C76.3Malignant neoplasm of pelvis
D59.39Other hemolytic-uremic syndrome
D86.85Sarcoid myocarditis
E03.5Myxedema coma
E05.00Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm
E05.01Thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm
E05.10Thyrotoxicosis with toxic single thyroid nodule without thyrotoxic crisis or storm
E05.11Thyrotoxicosis with toxic single thyroid nodule with thyrotoxic crisis or storm
E05.20Thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis or storm
E05.21Thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis or storm
E05.30Thyrotoxicosis from ectopic thyroid tissue without thyrotoxic crisis or storm
E05.31Thyrotoxicosis from ectopic thyroid tissue with thyrotoxic crisis or storm

Procedure codes: 83735.

Coverage indications, limitations and medical necessity

Magnesium is an essential ion in the human body, playing an important role in practically every major metabolic and biochemical process, supporting and maintaining cellular processes critical for human life. Magnesium plays an important physiological role, particularly in the brain, heart, and skeletal muscles. As the second most abundant intracellular cation after potassium, it is involved in over 600 enzymatic reactions including energy metabolism and protein synthesis. Intracellular magnesium stores are found in high concentration in mitochondria, where this element plays a pivotal role in the synthesis of adenosine triphosphate (ATP) from adenosine diphosphate (ADP) and inorganic phosphate. 1

Measurement of magnesium levels is used as an index to (1) metabolic activity in the body such as, carbohydrate metabolism, protein synthesis, nucleic acid synthesis, contraction of muscular tissue and (2) renal function, because 95% of magnesium is filtered through the glomerulus is reabsorbed in the tubules. 2

Covered Indications

Magnesium testing is considered reasonable and necessary under the following conditions:

1. H ypomagnesemia which can be induced by 2 major mechanisms: gastrointestinal or renal losses. Symptoms of low magnesium include: weakness, muscle cramps, confusion, irregular heartbeat, seizures.

Conditions which can produce hypomagnesemia include but are not limited to the following 2 :

• cardiac arrhythmias

• proton pump inhibitors

• alcohol

• uncontrolled diabetes mellitus

• hypercalcemia

• posttransplant patients

• other acquired tubular dysfunction

• malabsorption syndromes

• familial renal magnesium wasting

• volume expansion

• aminoglycoside antibiotics nephrotoxicity

• amphotericin B nephrotoxicity

• cisplatin

• pentamidine

• calcineurin inhibitors

• digoxin

• malabsorption syndromes

• parenteral alimentation with inadequate magnesium content

• diarrhea

• diabetic ketoacidosis

• diuretic therapy

• hyperaldosteronism

• hypoparathyroidism

• hyperthyroidism

• prolonged intravenous (IV) therapy

• prolonged nasogastric suction

• antibodies targeting the epidermal growth factor (EGF) receptor

2. H ypermagnesemia which can be induced in 2 settings: when kidney function is impaired and /or when a large magnesium load is given, whether intravenously, orally, or as an enema. Symptoms of high magnesium include: muscle weakness, fatigue, nausea and vomiting, trouble breathing, cardiac arrest.

Conditions which can produce hypermagnesemia include but are not limited to the following 2 :

• kidney impairment

• magnesium infusion

• oral magnesium ingestion

• magnesium enemas

• familial hypocalciuric hypercalcemia

• hypercatabolic states, such as tumor lysis syndrome

• diabetic ketoacidosis

• lithium ingestion

• milk alkali syndrome

• adrenal insufficiency

• rhabdomyolysis

Limitations

Services that are not reasonable and necessary cannot be covered by Medicare as published in CMS Internet-Only Manual, Pub. 100-08, Medicare Program Integrity Manual, Chapter 13, §13.5.4 Reasonable and Necessary Provision in an LCD and under Title XVIII of the Social Security Act §1862(a)(1)(A).

Summary of evidence (opening)

Schelling JR (1999) reported a case study of severe symptomatic hypermagnesemia that resulted from excess exogenous magnesium intake in a patient with renal failure. In conclusion, this report highlights that symptomatic hypermagnesemia is often iatrogenic, and caution should be used before prescribing magnesium containing medications in the context of acute renal failure. 4

Tong GM (2005) reviewed magnesium deficiency in critical illness by discussing its causes and its clinical implications based on the available clinical trials. The use of magnesium therapy is supported by clinical trials in the treatment of symptomatic hypomagnesemia and preeclampsia and is recommended for torsades de pointes. 5

Khan (2013) studied 3530 participants from the Framingham Offspring Study and were free of atrial fibrillation (AF) and cardiovascular disease (CVD). They used Cox proportional hazard regression analysis to examine the association between serum magnesium at baseline and risk of incident AF. They concluded that low serum magnesium was associated with the development of AF in a longitudinal, community-based cohort over 20 years of follow up. They found that those in the lowest quartile of serum magnesium were approximately 30% more likely to develop AF than those in the upper 3 quartiles. Although previous studies have reported an association between low serum magnesium and AF in the context of cardiac surgery, the present study was the first to demonstrate this association in the broader community. 6

Kieboom (2016) studied the association of serum magnesium levels with both coronary heart disease (CHD) and sudden cardiac death (SCD) within the Rotterdam Study, a prospective population-based cohort study among middle-aged and elderly persons with adjudicated end points and long term follow up. In this prospective population-based cohort study among 9820 participants with a median follow-up of 8.7 years, they found that low serum magnesium was associated with an increased risk of CHD mortality and SCD. When they excluded SCD from the CHD mortality end point, they found that higher serum magnesium levels were associated with a lower risk of non-sudden CHD mortality. 7

The contractor cites 10 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2023-01-22
Current revision effective
2024-09-12
Last reviewed by the contractor
2024-06-20
MCD version
8

Other related documents: A59275 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39400 cover?

Magnesium is an essential ion in the human body, playing an important role in practically every major metabolic and biochemical process, supporting and maintaining cellular processes critical for human life. Magnesium plays an important physiological role, particularly in the brain, heart, and skeletal muscles. As the second most abundant intracellular cation after potassium, it is involved in over 600 enzymatic… The full 441-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39400 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39400?

The companion billing and coding article A59186 lists 4,360 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39400?

A denial under LCD L39400 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59186's 4,360 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.